INT15896

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.65
First Reported 1986
Last Reported 2010
Negated 3
Speculated 0
Reported most in Body
Documents 18
Total Number 19
Disease Relevance 6.44
Pain Relevance 1.18

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (FANCB) nucleus (FANCB)
Anatomy Link Frequency
bone marrow 1
FANCB (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 139 95.52 Very High Very High Very High
rheumatoid arthritis 71 94.56 High High
palliative 1 93.28 High High
Neuropeptide 3 92.52 High High
Arthritis 24 91.44 High High
ischemia 4 85.32 High High
Infliximab 94 83.68 Quite High
Etanercept 31 82.92 Quite High
Pain 17 76.48 Quite High
Bioavailability 6 66.96 Quite High
Disease Link Frequency Relevance Heat
Hyperplasia 1 99.68 Very High Very High Very High
Sprains And Strains 141 98.38 Very High Very High Very High
Systemic Lupus Erythematosus 174 97.60 Very High Very High Very High
Myeloid Leukemia 7 96.20 Very High Very High Very High
Disease 296 95.88 Very High Very High Very High
INFLAMMATION 118 95.52 Very High Very High Very High
Rheumatoid Arthritis 72 94.56 High High
Age-related Macular Degeneration 208 92.40 High High
Staphylococcus Infection 27 88.92 High High
Retina Disease 4 85.32 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Ranibizumab (Lucentis®, Genentech, Inc., San Francisco, CA, USA) is a humanized antigen-binding fragment (Fab) that neutralizes all VEGF-A isoforms.
Gene_expression (neutralizes) of Fab
1) Confidence 0.65 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2698673 Disease Relevance 0.58 Pain Relevance 0.04
Ranibizumab was developed from a humanized Fab variant of A4.6.1, known as MB1.6.
Gene_expression (variant) of Fab
2) Confidence 0.65 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2698673 Disease Relevance 0.36 Pain Relevance 0.06
An additional 12/56 (21.3%) patients had impaired FAB score only; these included motor series (8 patients), conflicting instructions (7), inhibitory control (6), lexical fluency (7), conceptualization (6), and prehensile behavior (4).
Neg (impaired) Gene_expression (impaired) of FAB
3) Confidence 0.64 Published 2010 Journal Annals of Indian Academy of Neurology Section Body Doc Link PMC2859587 Disease Relevance 0.26 Pain Relevance 0
FAB-MS produces the protonated molecular ion of the peptide and allows direct measurement of underivatized peptides at the nanogram level, with increased molecular specificity.
Gene_expression (produces) of FAB-MS
4) Confidence 0.59 Published 1986 Journal J. Chromatogr. Section Abstract Doc Link 3525590 Disease Relevance 0.07 Pain Relevance 0.18
In the mixed group (cortical and subcortical), 5/63 (7.9%) patients had impaired MMSE and FAB; an additional 6/63 (9.52%) had impaired FAB only, which was as follows: motor series (6 patients), conflicting instructions (6), inhibitory control (5), lexical fluency (8), conceptualization (8), and prehensile behavior (2).
Neg (impaired) Gene_expression (impaired) of FAB
5) Confidence 0.56 Published 2010 Journal Annals of Indian Academy of Neurology Section Body Doc Link PMC2859587 Disease Relevance 0.20 Pain Relevance 0
[Detection of human anti-mouse antibody in patients receiving 111In-antimyosin Fab: multicenter clinical study in Japan].
Gene_expression (receiving) of Fab
6) Confidence 0.45 Published 1991 Journal Kaku Igaku Section Title Doc Link 1770644 Disease Relevance 0.30 Pain Relevance 0.08
Importantly however, any overlap between NRF and CRF could be excluded based on the following arguments: (a) Western blotting shows no IgG4 Fab- Ig Fc (CRF) interaction and (b) ELISA showed that serum level of IgG4 bound to each IgG subclass correlated well with the serum IgG4 level itself (i.e. the totality of IgG4-Ig interaction is through Fc-Fc engagement), and (c) the reciprocal absence of any link between IgG-bound IgG4 levels and RF, excluding therefore any CRF reactivity (Figure 5).
Neg (no) Gene_expression (blotting) of Fab
7) Confidence 0.19 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2249926 Disease Relevance 0.20 Pain Relevance 0.07
The comparison between OuJ and HeJ mice, for example, did not produce any detectable differences in HR regulation during either FACB or O3CB exposure.
Gene_expression (exposure) of FACB
8) Confidence 0.15 Published 2008 Journal Environ Health Perspect Section Body Doc Link PMC2516564 Disease Relevance 0.54 Pain Relevance 0
The strain difference in HRV responses appeared to be dependent on O3 preexposure, because FACB exposure did not produce significant changes in these cardiac functional parameters.
Gene_expression (exposure) of FACB associated with sprains and strains
9) Confidence 0.15 Published 2008 Journal Environ Health Perspect Section Body Doc Link PMC2516564 Disease Relevance 0.59 Pain Relevance 0
Specifically, in B6 mice the MA O2 pulse after FACB and O3CB exposures was significantly (p < 0.01) greater relative to FAFA exposure.


Gene_expression (exposures) of FACB
10) Confidence 0.15 Published 2008 Journal Environ Health Perspect Section Body Doc Link PMC2516564 Disease Relevance 0.63 Pain Relevance 0
Two representative proteins highlighted were leukotriene A4 hydrolase (1HS6) and Fab fragment of IgG (1DBJ).
Gene_expression (fragment) of Fab
11) Confidence 0.15 Published 2009 Journal PLoS Computational Biology Section Body Doc Link PMC2704868 Disease Relevance 0.40 Pain Relevance 0.05
agent, a nanomolecule comprising a humanized Fab’ antibody fragment against TNF?
Gene_expression (antibody) of Fab
12) Confidence 0.12 Published 2007 Journal International Journal of Nanomedicine Section Abstract Doc Link PMC2673817 Disease Relevance 0.55 Pain Relevance 0.23
Fab fragments
Gene_expression (fragments) of Fab
13) Confidence 0.10 Published 2007 Journal International Journal of Nanomedicine Section Body Doc Link PMC2673818 Disease Relevance 0.29 Pain Relevance 0.07
A potential solution has been to express fragments of antibodies such as Fab' in microbial expression systems such as Escherichia coli.
Gene_expression (express) of Fab
14) Confidence 0.10 Published 2007 Journal International Journal of Nanomedicine Section Body Doc Link PMC2673818 Disease Relevance 0 Pain Relevance 0
Certolizumab pegol (CDP870) is an example of a PEGylated Fab fragment of a humanized anti-TNF alpha antibody (UCB 2005; National Horizon Scanning Centre 2004) that has been developed for the treatment of Crohn’s disease (National Horizon Scanning Centre 2004; Winter et al 2004; Schreiber et al 2005a, 2005b) and rheumatoid arthritis (Choy et al 2002; Keystone et al 2001)
Gene_expression (fragment) of Fab associated with rheumatoid arthritis and disease
15) Confidence 0.10 Published 2007 Journal International Journal of Nanomedicine Section Body Doc Link PMC2673818 Disease Relevance 0.34 Pain Relevance 0.10
All bone marrow samples were hypercellular, classified as FAB types M2 in 2 cases, M4 in 6, and M5 in one case.
Gene_expression (types) of FAB in bone marrow associated with hyperplasia
16) Confidence 0.07 Published 2010 Journal Vnitr Lek Section Abstract Doc Link 20184110 Disease Relevance 0.82 Pain Relevance 0.09
Fab fragment?
Gene_expression (fragment) of Fab
17) Confidence 0.06 Published 2010 Journal Autoimmune Diseases Section Body Doc Link PMC2989704 Disease Relevance 0.26 Pain Relevance 0
Gololobov et al. [42, 43] and Rodkey et al. [30] used a modification of this approach to purify the mouse monoclonal anti-ssDNA antibody and its Fab fragment (obtained by papain hydrolysis) with excellent results with respect to their activity.
Gene_expression (fragment) of Fab
18) Confidence 0.06 Published 2010 Journal Autoimmune Diseases Section Body Doc Link PMC2989704 Disease Relevance 0 Pain Relevance 0
A study of pregnant and lactating rats compared TN3 PEGylated Fab’ (comparable to certolizumab) and TN3 IgG1 antibody (comparable to the classic anti-TNF?
Gene_expression (antibody) of Fab
19) Confidence 0.05 Published 2010 Journal International Journal of Women's Health Section Body Doc Link PMC2971732 Disease Relevance 0.06 Pain Relevance 0.20

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox